Furthermore, although there is evidence supporting the safety and even the protective role of the RAAS blockers during COVID-19, a recently published randomized clinical trial in critically ill patients with COVID-19 showed that initiation of treatment with an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker during hospitalization did not ameliorate, and likely worsened, clinical outcomes [20]. Here, ACE is linked to COVID-19.